Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity.
作者信息
Anthi Anastasia, Stagaki Eleni, Rallidis Loukianos, Konstantonis Dimitrios, Evangelopoulos Maria-Eleftheria, Voumvourakis Konstantinos, Armaganidis Apostolos, Orfanos Stylianos E
机构信息
Pulmonary Hypertension Clinic, "Attikon" Hospital, Athens, Greece.
2nd Dept of Critical Care, National and Kapodistrian University of Athens, "Attikon" Hospital, Athens, Greece.
出版信息
ERJ Open Res. 2020 Mar 16;6(1). doi: 10.1183/23120541.00328-2019. eCollection 2020 Jan.
Abstract
摘要
相似文献
1
Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity.
ERJ Open Res. 2020 Mar 16;6(1). doi: 10.1183/23120541.00328-2019. eCollection 2020 Jan.
2
Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.与干扰素-β治疗多发性硬化症相关的可逆性肺动脉高压。
Can Respir J. 2015 Sep-Oct;22(5):263-5. doi: 10.1155/2015/181535. Epub 2015 Jun 17.
3
Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.与多发性硬化症干扰素-β治疗相关的肺动脉高压。病例报告及文献复习。
Mult Scler Relat Disord. 2019 Feb;28:273-275. doi: 10.1016/j.msard.2019.01.018. Epub 2019 Jan 6.
4
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.与干扰素-β治疗多发性硬化症相关的可逆性肺动脉高压
Iran J Neurol. 2016 Jan 5;15(1):54-6.
5
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.多发性硬化症患者中干扰素 β-1a 长期治疗与肺动脉高压相关。
Mult Scler. 2016 Oct;22(11):1495-1498. doi: 10.1177/1352458515618020. Epub 2015 Nov 12.
6
Interferon-induced pulmonary hypertension: an update.干扰素诱导的肺动脉高压：最新进展
Curr Opin Pulm Med. 2016 Sep;22(5):415-20. doi: 10.1097/MCP.0000000000000307.
7
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients.基因变异与干扰素-β 1a治疗对多发性硬化症患者肺动脉高压发展的相互强化作用。
Pulm Circ. 2019 Nov 18;9(3):2045894019872192. doi: 10.1177/2045894019872192. eCollection 2019 Jul-Sep.
8
Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.与干扰素β治疗多发性硬化症相关的肺动脉高压：一例报告
Mult Scler. 2009 Jul;15(7):885-6. doi: 10.1177/1352458509104593. Epub 2009 May 22.
9
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.不同磷酸二酯酶-5抑制剂对干扰素-α诱导的肺动脉高压的长期治疗：一例报告
Cardiovasc Ultrasound. 2005 Sep 2;3:26. doi: 10.1186/1476-7120-3-26.
10
Pulmonary arterial hypertension associated with interferon therapy: a population-based study.与干扰素治疗相关的肺动脉高压：一项基于人群的研究。
Multidiscip Respir Med. 2017 Jan 17;12:1. doi: 10.1186/s40248-016-0082-z. eCollection 2017.
引用本文的文献
1
Intestinal IFNα4 promotes 15-HETE diet-induced pulmonary hypertension.肠干扰素α4促进饮食诱导的 15-HETE 肺动脉高压。
Respir Res. 2024 Nov 28;25(1):419. doi: 10.1186/s12931-024-03046-z.
本文引用的文献
1
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients.基因变异与干扰素-β 1a治疗对多发性硬化症患者肺动脉高压发展的相互强化作用。
Pulm Circ. 2019 Nov 18;9(3):2045894019872192. doi: 10.1177/2045894019872192. eCollection 2019 Jul-Sep.
2
Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.与多发性硬化症干扰素-β治疗相关的肺动脉高压。病例报告及文献复习。
Mult Scler Relat Disord. 2019 Feb;28:273-275. doi: 10.1016/j.msard.2019.01.018. Epub 2019 Jan 6.
3
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.血流动力学定义和肺动脉高压的最新临床分类。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
4
Pulmonary arterial hypertension associated with interferon therapy: a population-based study.与干扰素治疗相关的肺动脉高压：一项基于人群的研究。
Multidiscip Respir Med. 2017 Jan 17;12:1. doi: 10.1186/s40248-016-0082-z. eCollection 2017.
5
Pulmonary arterial hypertension in patients treated with interferon.接受干扰素治疗患者的肺动脉高压
Eur Respir J. 2015 Dec;46(6):1851-3. doi: 10.1183/13993003.01376-2015.
6
Pulmonary arterial hypertension in patients treated with interferon.接受干扰素治疗的患者的肺动脉高压
Eur Respir J. 2015 Dec;46(6):1849-51. doi: 10.1183/13993003.02327-2014.
7
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.多发性硬化症患者中干扰素 β-1a 长期治疗与肺动脉高压相关。
Mult Scler. 2016 Oct;22(11):1495-1498. doi: 10.1177/1352458515618020. Epub 2015 Nov 12.
8
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断与治疗工作组制定：该指南得到了欧洲儿科和先天性心脏病协会（AEPC）以及国际心肺移植学会（ISHLT）的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
9
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
10
Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.与干扰素-β治疗多发性硬化症相关的可逆性肺动脉高压。
Can Respir J. 2015 Sep-Oct;22(5):263-5. doi: 10.1155/2015/181535. Epub 2015 Jun 17.
Zotero 插件